CompletedNot Applicable

Altered Faecal Microbiome and Metabolome in CT1D, AT1D and T2D

China372 participantsStarted 2019-02-01

Plain-language summary

To elucidate the characteristics of global gut microbiota and fecal/serum metabolites in patients with childhood-onset type 1 diabetes, adult-onset type 1 diabetes or type 2 diabetes.

Who can participate

Age range5 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diabetes diagnosed according to the report of WHO in 1999；
✓. Aged between 5 and 70 years old;

Exclusion criteria

✕. Severe chronic cardiovascular or cerebrovascular disease；
✕. Severe abnormalities in liver or renal function;
✕. Hyperthyroidism; or other autoimmune diseases;
✕. Tumors, surgery or pregnancy;
✕. Treatments with oral hypoglycemic agents or immunomodulators;
✕. Subjects who had taken probiotics, prebiotics within one week or antibiotics within one month.

What they're measuring

Differences of β diversity of gut microbiota between diabetic groups and healthy control.

Timeframe: at baseline

Trial details

NCT IDNCT05252728

SponsorSecond Xiangya Hospital of Central South University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04-30

View on ClinicalTrials.gov More Type 1 Diabetes Mellitus Maturity Onset trials